A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102)

NCT03235570 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
44
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Incyte Corporation